Subtopic Deep Dive
Transcatheter Aortic Valve Replacement Outcomes
Research Guide
What is Transcatheter Aortic Valve Replacement Outcomes?
Transcatheter Aortic Valve Replacement (TAVR) Outcomes evaluate the efficacy, safety, and long-term survival of TAVR procedures compared to surgical aortic valve replacement (SAVR) in high-risk and intermediate-risk patients with severe aortic stenosis.
TAVR demonstrates similar 1-year survival rates to SAVR in high-risk patients despite differing periprocedural risks (Smith et al., 2011, 6220 citations). Self-expanding prostheses show higher 1-year survival than SAVR in increased surgical risk patients (Adams et al., 2014, 2835 citations). Real-world registries confirm TAVR as a viable option in elderly high-risk populations (Gilard et al., 2012, 1219 citations). Over 10 papers from provided lists exceed 600 citations each.
Why It Matters
TAVR expands valve replacement access to high-risk patients unsuitable for open surgery, reducing periprocedural mortality as shown in the PARTNER trial (Smith et al., 2011). Self-expanding valves improve 1-year survival over SAVR in surgical risk cohorts (Adams et al., 2014). Registries like SOURCE and FRANCE2 validate TAVR safety in real-world high-risk elderly with aortic stenosis (Thomas et al., 2010; Gilard et al., 2012). Guidelines integrate TAVR for aortic disease management (Erbel et al., 2014).
Key Research Challenges
Long-term Durability Assessment
TAVR prostheses face uncertain durability beyond 5 years compared to SAVR. Self-expanding vs balloon-expandable valves show varying hemodynamic outcomes (Adams et al., 2014; Pîbarot and Dumesnil, 2009). Registries highlight need for extended follow-up (Gilard et al., 2012).
Periprocedural Risk Differences
TAVR exhibits higher stroke rates but lower bleeding risks than SAVR in high-risk patients. PARTNER trial identified divergent adverse events despite equivalent survival (Smith et al., 2011). SOURCE registry reported 30-day outcomes with specific complication profiles (Thomas et al., 2010).
Patient Selection Optimization
Risk stratification remains challenging for intermediate-risk expansion from high-risk cohorts. Early percutaneous trials emphasized selected high-risk suitability (Webb et al., 2007). Guidelines stress imaging and comorbidity assessment (Erbel et al., 2014).
Essential Papers
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
Craig R. Smith, Martin B. Leon, Michael J. Mack et al. · 2011 · New England Journal of Medicine · 6.2K citations
In high-risk patients with severe aortic stenosis, transcatheter and surgical procedures for aortic-valve replacement were associated with similar rates of survival at 1 year, although there were i...
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases
Authors Task Force Members, Raimund Erbel, Victor Aboyans et al. · 2014 · European Heart Journal · 4.3K citations
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the D...
Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis
David Adams, Jeffrey J. Popma, Michael J. Reardon et al. · 2014 · New England Journal of Medicine · 2.8K citations
In patients with severe aortic stenosis who are at increased surgical risk, TAVR with a self-expanding transcatheter aortic-valve bioprosthesis was associated with a significantly higher rate of su...
Registry of Transcatheter Aortic-Valve Implantation in High-Risk Patients
Martine Gilard, Hélène Eltchaninoff, Bernard Iung et al. · 2012 · New England Journal of Medicine · 1.2K citations
This prospective registry study reflected real-life TAVI experience in high-risk elderly patients with aortic stenosis, in whom TAVI appeared to be a reasonable option. (Funded by Edwards Lifescien...
Percutaneous Transarterial Aortic Valve Replacement in Selected High-Risk Patients With Aortic Stenosis
John G. Webb, Sanjeevan Pasupati, Karin H. Humphries et al. · 2007 · Circulation · 1.0K citations
Background— Percutaneous aortic valve replacement represents an endovascular alternative to conventional open heart surgery without the need for sternotomy, aortotomy, or cardiopulmonary bypass. Me...
Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: Changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database
James Brown, Sean M. O’Brien, Changfu Wu et al. · 2009 · Journal of Thoracic and Cardiovascular Surgery · 931 citations
Thirty-Day Results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry
Martyn Thomas, Gerhard Schymik, Thomas Walther et al. · 2010 · Circulation · 877 citations
Background— Transcatheter aortic valve implantation was developed to mitigate the mortality and morbidity associated with high-risk traditional aortic valve replacement. The Edwards SAPIEN valve wa...
Reading Guide
Foundational Papers
Start with Smith et al. (2011) for PARTNER trial establishing TAVR equivalence to SAVR in high-risk patients; follow with Adams et al. (2014) on self-expanding superiority and Gilard et al. (2012) for real-world registry validation.
Recent Advances
Lindman et al. (2016) on calcific aortic stenosis context; Erbel et al. (2014) ESC guidelines integrating TAVR recommendations.
Core Methods
Randomized controlled trials (PARTNER, COREVALVE), prospective registries (FRANCE2, SOURCE), hemodynamic assessments via echocardiography, and risk stratification per STS scores.
How PapersFlow Helps You Research Transcatheter Aortic Valve Replacement Outcomes
Discover & Search
Research Agent uses citationGraph on Smith et al. (2011) to map 6220-citation PARTNER trial connections, revealing Gilard et al. (2012) registry and Adams et al. (2014) self-expanding prosthesis studies. exaSearch queries 'TAVR vs SAVR long-term outcomes high-risk' surfaces 250M+ OpenAlex papers filtered by citations. findSimilarPapers expands to prosthesis comparisons.
Analyze & Verify
Analysis Agent applies readPaperContent to extract 1-year survival rates from Smith et al. (2011) and Adams et al. (2014), then verifyResponse with CoVe cross-checks against Gilard et al. (2012) registry data. runPythonAnalysis computes meta-analysis statistics on periprocedural risks using pandas/NumPy sandbox. GRADE grading assesses evidence quality for high-risk TAVR efficacy.
Synthesize & Write
Synthesis Agent detects gaps in long-term TAVR durability via contradiction flagging between early trials (Webb et al., 2007) and registries (Thomas et al., 2010). Writing Agent employs latexEditText for outcomes tables, latexSyncCitations for 10+ provided papers, and latexCompile for polished review. exportMermaid visualizes TAVR vs SAVR survival curves.
Use Cases
"Compare 1-year survival rates in TAVR high-risk patients across PARTNER and COREVALVE trials"
Research Agent → searchPapers('PARTNER TAVR') → citationGraph(Smith 2011) → Analysis Agent → readPaperContent(Adams 2014) → runPythonAnalysis(pandas survival meta-analysis) → GRADE report with verified rates.
"Draft LaTeX section on TAVR periprocedural risks vs SAVR"
Synthesis Agent → gap detection(Smith 2011, Thomas 2010) → Writing Agent → latexEditText('risks table') → latexSyncCitations(Gilard 2012 et al.) → latexCompile → PDF with formatted outcomes comparison.
"Find code for TAVR registry data analysis"
Research Agent → searchPapers('TAVR registry analysis') → paperExtractUrls(Gilard 2012) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis(local sandbox on extracted stats code) → matplotlib survival plots.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers('TAVR outcomes high-risk') → citationGraph → 50+ papers → structured report with GRADE on Smith et al. (2011) survival data. DeepScan applies 7-step CoVe: readPaperContent(Adams 2014) → verifyResponse(periprocedural risks) → statistical checkpoints. Theorizer generates hypotheses on self-expanding prosthesis superiority from Adams et al. (2014) and registries.
Frequently Asked Questions
What defines TAVR outcomes research?
TAVR outcomes research measures efficacy, safety, and survival of transcatheter procedures versus SAVR in aortic stenosis patients, focusing on high-risk groups (Smith et al., 2011).
What are key methods in TAVR studies?
Randomized trials like PARTNER compare 1-year survival (Smith et al., 2011); registries like FRANCE2 assess real-world 30-day results (Gilard et al., 2012); imaging evaluates prosthesis performance (Pîbarot and Dumesnil, 2009).
What are the most cited TAVR papers?
Smith et al. (2011, 6220 citations) on PARTNER trial; Adams et al. (2014, 2835 citations) on self-expanding prosthesis; Erbel et al. (2014, 4317 citations) ESC guidelines.
What open problems exist in TAVR outcomes?
Long-term valve durability beyond 5 years, optimal patient selection for intermediate risk, and prosthesis type comparisons remain unresolved (Adams et al., 2014; Gilard et al., 2012).
Research Aortic Disease and Treatment Approaches with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Transcatheter Aortic Valve Replacement Outcomes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers